Gordon Campbell | Parliament TV | Parliament Today | News Video | Crime | Employers | Housing | Immigration | Legal | Local Govt. | Maori | Welfare | Unions | Youth | Search

 

Multiple Sclerosis NZ Review of medicinal cannabis research

Review of Current Research Regarding the Use of Medicinal Cannabis for MS And MND Symptom Management

A report for Multiple Sclerosis New Zealand and Motor Neurone Disease New Zealand

December 2017, by Kerry Walker, MSc.

Executive Summary

With the increasing interest in Medicinal Cannabis for managing pain and spasticity in MS and other chronic conditions Multiple Sclerosis NZ and Motor Neurone New Zealand jointly commissioned, in 2017, the attached written report to:

1. Review and report on current research on the use of medicinal cannabis for multiple sclerosis (MS) and motor neurone disease (MND) symptom management; 2. Examine the risks and the risk/benefits of using medicinal cannabis; and 3. Review the current international recommendations for the safe use of medicinal cannabis for MS and MND symptom management.

The report is designed to contribute to an informed debate about the information and research into the benefits that cannabis can provide medicinally. The information is intended to allow the reader to formulate their own informed decision as to their support or otherwise for use. This supporting executive summary has been compiled by the Multiple Sclerosis Society of New Zealand and focusses on the impact to people with MS only as we do not have the mandate to speak on behalf of other organisations or conditions.

The term ‘medicinal’ in this report refers to the situation in which cannabis is used and in this case, for a medical need rather than recreational use. It does not distinguish between cannabis that is a pharmaceutical grade product from that which could be grown or procured privately. This report reviews the benefits and risks associated with use for medicinal purposes.

Pain and spasticity are well known effects of MS and can have a detrimental effect on a person’s mental health, wellbeing and quality of life. Many find little or no relief in the currently available medications, which also possess their own side effects and dependencies. This has resulted in the need to explore alternative options. Several years of global studies and research into the positive effects of the use of cannabis has proven that positive benefits can be provided to people with MS in the symptomatic management of pain and spasticity.

Pain can be neuropathic (arising from damage to the nervous system), related to muscle spasms, nerve damage or a combination. Studies have shown cannabis can reduce neuropathic (nerve damage) pain by 30% and is more effective than gabapentin, the current frontline therapy for neuropathic pain. In a 2016 study of chronic pain (both neuropathic and non-neuropathic), 69.5% of patients reported a significant reduction in pain scores and improvement in quality of life. Additionally, 44% of participants who were taking opioids at the start of the study had completely discontinued use by the end.

The majority of medicinal cannabis studies have researched spasticity in muscles where they involuntarily contract. This causes tightness, stiffness and pain in muscles and can interfere with normal movement. However, it should be noted that spasticity also affects other internal organs including the bladder which have not been studied. It has been known since 2000 that cannabinoids can control spasticity in MS. Studies have shown that patients have reported a 29.4% improvement in muscle stiffness through cannabis use. In New Zealand the only pharmaceutical grade cannabis product, Sativex, has been approved by MedSafe for use in MS spasticity but not pain. PHARMAC have declined to fund Sativex for use in MS spasticity and currently must be paid for privately.

The results of many of the studies focus on the patient reported outcomes. This should not diminish the importance of the results. Pain and spasticity are significant contributors to people with MS having poor mental health, depression, inability to work, contribute to their communities or look after their families. Many people with chronic pain and spasticity, who would benefit most from access to medicinal cannabis, do not have access to other treatments in New Zealand. Symptom management is the only option available.

It is also important to highlight that MS is a chronic but not terminal condition which people can live with for 30+ years. Safe, free and legal access will support these people who live with chronic pain and spasticity for many years, rather than at the end of their life. Through education, informed consent and control of the products available, people with MS should be able to make their own fully-informed decisions about whether the benefits outweigh the potential risks.

MSNZ supports regulated cannabis-based products for medicinal purposes being made available, free and legally, to people with MS for the management of pain and spasticity, on prescription from their GP or neurologist. The Society recommends people with MS educate themselves about the benefits and potential risks of any treatment option and make decisions in consultation with their families and primary health care providers.

Read the full report here:


© Scoop Media

 
 
 
Parliament Headlines | Politics Headlines | Regional Headlines

Whakaari/White Island: A Minute’s Silence For Victims

A minute’s silence will be observed at 2.11pm on Monday 16 December in honour of the victims of the Whakaari White Island eruption, Prime Minister Jacinda Ardern has confirmed...

The minute’s silence will be exactly one week after the eruption started on Monday 9 December. More>>

Gordon Campbell: On What An Inquiry Might Look Like
Presumably, if there is to be a ministerial inquiry (at the very least) into the Whakaari/White Island disaster, it will need to be a joint ministerial inquiry. That’s because the relevant areas of responsibility seem to be so deeply interwoven... More>>

 

More Discussions: National On Housing, Transport And Infrastructure

National has today released the ninth and tenth in our series of discussion documents, which contain a range of proposals to ensure New Zealand has the high-quality housing and infrastructure it needs to prosper, Leader of the Opposition Simon Bridges says. More>>

ALSO:

Trains: Govt's Plans For Rail

The Government has released its long term vision for a sustainable 21st Century rail network that gets our cities moving, connects our regions and gets more freight off the roads. More>>

ALSO:

Gordon Campbell: On Welfare Vs Infrastructure Spending

If New Zealand has a pressing need to stimulate its flagging economy, it seems very weird that the government is choosing a $12 billion package of infrastructure spending – mainly on road and rail – that by definition, will take a very long time to deliver their stimulatory benefits ... More>>

New Reports: "Immediate Commitment To Doing Justice Differently"

Justice Minister Andrew Little released two reports today, Turuki! Turuki! from Te Uepū Hāpai I te Ora, and Te Tangi o te Manawanui: Recommendations for Reform from the Chief Victims Advisor. Both recommend a fresh approach to the way criminal justice has been approached... More>>

ALSO:

"Heart-Breaking And Confronting": Surgical Mesh Restorative Justice Report

Minister Genter: “People have talked about losing the life they had enjoyed before surgical mesh harmed them – the loss of a steady job, the ability to exercise, a loving relationship in some cases. Others described the chronic pain they experienced..." More>>

ALSO:

Law Foundation: Government Decryption Powers Must Respect Privacy

The power of government to order users and companies to decrypt encrypted data and devices needs stronger privacy protections and additional safeguards, according to a study published by researchers at the University of Waikato. More>>

 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL
 


 

InfoPages News Channels